NDA 020835 · Apil
Actonel
Risedronate Sodium · Oral
NovelLast checked: Nov 20, 2026Latest source record: Feb 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Mar 27, 1998
Approved uses
12
Original approval plus efficacy supplements
Registered trials
95
42 Phase 3, 2 recruiting
FAERS reports
30,757
25,781 serious, 2,978 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 12, 2026.
Risedronate Sodium is a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.3 ) Treatment of Paget’s disease ( 1.4 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.5 ) 1.1 Postmenopausal Osteoporosis Risedronate Sodium is indicated for the treatment and prevention of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, Risedronate Sodium reduces the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [ see Clinical Studies ( 14.1 , 14.2 ) ]. 1.2 Osteoporosis in Men Risedronate Sodium is indicated for treatment to increase bone mass in men with osteoporosis. 1.3 Glucocorticoid-Induced Osteoporosis Risedronate Sodium is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of greater than or equal to 7.5 mg of prednisone or equivalent) for chronic diseases. Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. 1.4 Paget’s Disease Risedronate Sodium is indicated for treatment of Paget’s disease of bone in men and women. 1.5 Important Limitations of Use The optimal duration of use has not been determined. The safety and effectiveness of Risedronate Sodium for the treatment of osteoporosis are based on clinical data of three years duration. All patients on bisphosphonate therapy should have the need for continued therapy...
Mechanism: Risedronate Sodium has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent. At the cellular level, Risedronate Sodium inhibits osteoclasts. The osteoclasts adhere normally to the bone surface, but show evidence of reduced active resorption (for example, lack of ruffled border). Histomorphometry in rats, dogs, and minipigs showed that Risedronate Sodium treatment reduces bone turnover (activation frequency, that is, the rate at which bone remodeling sites are activated) and bone resorption at remodeling sites.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 23, 2009 Supplement 35 · Efficacy · priority review Pediatric Clinical Pharmacology ReviewPediatric Statistical ReviewPediatric Medical Review
- Apr 22, 2008 Supplement 30 · Efficacy Letter
- Apr 16, 2007 Supplement 25 · Efficacy LabelLetter
- Aug 11, 2006 Supplement 22 · Efficacy LabelLetter
- Jan 24, 2006 Supplement 19 · Efficacy LetterLabel
- May 17, 2002 Supplement 8 · Efficacy LetterLabel
- May 17, 2002 Supplement 9 · Efficacy Letter
- Apr 14, 2000 Supplement 4 · Efficacy · priority review LetterLabelReview
- Apr 14, 2000 Supplement 2 · Efficacy ReviewLabelLetter
- Apr 14, 2000 Supplement 3 · Efficacy ReviewLetterLabel
- Apr 14, 2000 Supplement 1 · Efficacy · priority review LetterLabelReview
- Mar 27, 1998 Original approval · Type 1 - New Molecular Entity LetterReviewPediatric Medical Review
5 products under this application
- ACTONEL · RISEDRONATE SODIUM 75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- ACTONEL · RISEDRONATE SODIUM 5MG · TABLET, ORAL · Discontinued · TE AB
- ACTONEL · RISEDRONATE SODIUM 150MG · TABLET, ORAL · Prescription · TE AB
- ACTONEL · RISEDRONATE SODIUM 35MG · TABLET, ORAL · Prescription · TE AB
- ACTONEL · RISEDRONATE SODIUM 30MG · TABLET, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Risedronate" as an intervention, any sponsor and status, largest first.
- POWER Point of Care Effect on Satisfaction of TreatmentPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00549068 · 2,433 participants · Start Feb 2003
Drug: Risedronate Sodium (Actonel) · For: Osteoporosis, Postmenopausal
- VERtebral Fracture Treatment Comparisons in Osteoporotic WomenPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01709110 · 1,366 participants · Start Oct 2012 · Primary completion Jul 2016
Drug: Teriparatide; Risedronate and 3 more · For: Postmenopausal Osteoporosis
Sites: Birmingham, Alabama; Concord, California; Fresno, California · 103 sites in all
- A Study of Monthly Risedronate for OsteoporosisPivotal-lookingCompleted
Warner ChilcottIndustry
NCT00247273 · 1,294 participants · Start Oct 2005 · Primary completion Mar 2008
Drug: risedronate; risedronate · For: Postmenopausal Osteoporosis
Sites: Lakewood, Colorado; Gainesville, Georgia; Bethesda, Maryland · 49 sites in all
- Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary OsteoporosisPivotal-lookingCompleted
Chugai PharmaceuticalIndustry
NCT00447915 · 1,265 participants · Start Mar 2007 · Primary completion Aug 2011
Drug: ibandronic acid 0.5mg; RIS placebo and 3 more · For: Primary Osteoporosis
Sites: Chubu/Kansai, Japan; Chugoku/Kyusyu, Japan; Hokkaido/Tohoku, Japan · 4 sites in all
- Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal WomenPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00358176 · 1,231 participants · Start Jul 2004 · Primary completion Mar 2007
Drug: Risedronate (HMR4003) · For: Osteoporosis Postmenopausal
Sites: Bridgewater, New Jersey; San Isidro, Argentina; Macquarie Park, Australia · 11 sites in all
- A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092014 · 1,053 participants · Start Sep 1, 2002 · Primary completion Apr 1, 2004
Drug: Alendronate; Risedronate 35 mg and 2 more · For: Postmenopausal Osteoporosis
- Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With OsteoporosisPivotal-lookingCompleted
Hanlim Pharm. Co., Ltd.Industry
NCT01675297 · 1,053 participants · Start Jul 4, 2011 · Primary completion Dec 2013
Drug: Risedronate/Cholecalciferol combination; Risedronate · For: Osteoporosis
Sites: Seoul, South Korea
- A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092040 · 936 participants · Start Mar 18, 2003 · Primary completion Oct 18, 2004
Drug: MK0217, alendronate sodium/Duration of Intervention: 12 mo; Comparator: risedronate / Duration of Intervention: 12 mo · For: Osteoporosis, Postmenopausal
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- arthralgia3,863
- pain3,826
- drug ineffective3,764
- dyspnoea3,107
- nausea3,083
- fatigue3,043
- vomiting3,040
- off label use2,973
- diarrhoea2,773
- drug hypersensitivity2,687
- pneumonia2,667
- malaise2,504
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,012 |
| 2005 | 1,174 |
| 2006 | 1,044 |
| 2007 | 1,141 |
| 2008 | 1,332 |
| 2009 | 1,656 |
| 2010 | 1,731 |
| 2011 | 1,455 |
| 2012 | 1,813 |
| 2013 | 1,177 |
| 2014 | 902 |
| 2015 | 1,117 |
| 2016 | 1,124 |
| 2017 | 898 |
| 2018 | 930 |
| 2019 | 1,240 |
| 2020 | 1,521 |
| 2021 | 1,401 |
| 2022 | 1,647 |
| 2023 | 1,672 |
| 2024 | 1,911 |
| 2025 | 1,780 |
| 2026 | 1,078 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Actonel (Risedronate Sodium)
2024 spending
$970K
Beneficiaries
352
1,426 claims
Per beneficiary
$2,756
$171.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,358,869 |
| 2021 | $1,788,278 |
| 2022 | $1,460,182 |
| 2023 | $1,132,973 |
| 2024 | $970,089 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.
Kobayashi T, Morimoto T, Ito K, et al. · Osteoporos Int 2024 · Meta-Analysis, Comparative Study
- The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR, Nicolopoulos K, Stringer D, et al. · Calcif Tissue Int 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Kendler DL, Marin F, Zerbini CAF, et al. · Lancet 2018 · Multicenter Study, Randomized Controlled Trial
- Impact of bisphosphonate drugs on dental implant healing and peri-implant hard and soft tissues: a systematic review.
Fiorillo L, Cicciù M, Tözüm TF, et al. · BMC Oral Health 2022 · Systematic Review
- Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
Deardorff WJ, Cenzer I, Nguyen B, et al. · JAMA Intern Med 2022 · Meta-Analysis, Research Support, N.I.H., Extramural
- Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Barrionuevo P, Kapoor E, Asi N, et al. · J Clin Endocrinol Metab 2019 · Research Support, Non-U.S. Gov't, Network Meta-Analysis
Sponsor: Apil
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.